Related Experiment Videos
LG 30435, a new potential antiasthmatic agent
F Berti1, L Daffonchio, F Magni
1Institute of Pharmacological Sciences, University of Milan, Italy.
The European Respiratory Journal
|October 1, 1989
Summary
LG 30435, a novel phenothiazine derivative, effectively reduces bronchoconstriction and thromboxane-A2 (TxA2) generation in guinea pigs. This compound shows potential for treating asthma by inhibiting allergic airway responses.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Immunology
Background:
- Asthma involves complex immunological and mediator-induced responses affecting respiratory mechanics.
- Thromboxane-A2 (TxA2) plays a significant role in the pathophysiology of asthma and allergic reactions.
Purpose of the Study:
- To evaluate the efficacy of LG 30435, a new phenothiazine derivative, in preventing mediator-induced bronchoconstriction and TxA2 generation.
- To assess the protective effects of LG 30435 against lung anaphylaxis in a sensitized guinea pig model.
Main Methods:
- Administered LG 30435 to anesthetized guinea pigs and measured respiratory mechanics and TxA2 levels.
- Utilized various stimuli including histamine, acetylcholine, leukotriene C4 (LTC4), PAF-acether, and ovalbumin challenge.
- Determined TxA2 (as TxB2) generation in isolated guinea pig lungs.
Main Results:
- LG 30435 dose-dependently inhibited bronchoconstriction and TxA2 generation induced by multiple stimuli.
- Both intravenous and aerosol administration of LG 30435 reduced airway resistance and TxA2 increase post-ovalbumin challenge.
- LG 30435 inhibited TxB2 generation by anaphylactic mediators in isolated lungs, but not by arachidonic acid.
Conclusions:
- LG 30435 exhibits significant bronchodilator activity against diverse stimuli.
- The compound demonstrates protective properties in lung anaphylaxis, suggesting therapeutic potential for asthma treatment.